Get the Stockscreener App
1.96
2.08%
0.04
After Hours:
1.94
-0.02
-1.02%
Prokidney Corp stock is traded at $1.96, with a volume of 579.60K.
It is up +2.08% in the last 24 hours and up +8.29% over the past month.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$1.92
Open:
$1.95
24h Volume:
579.60K
Relative Volume:
0.70
Market Cap:
$278.30M
Revenue:
$893.00K
Net Income/Loss:
$-151.61M
P/E Ratio:
-3.8043
EPS:
-0.5152
Net Cash Flow:
$-135.31M
1W Performance:
+7.69%
1M Performance:
+8.29%
6M Performance:
-30.25%
1Y Performance:
+184.06%
1-Day Range:
$1.87
$1.99
1-Week Range:
$1.82
$1.99
52-Week Range:
$0.54
$7.13
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.96 | 272.62M | 893.00K | -151.61M | -135.31M | -0.5152 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | H.C. Wainwright | Buy |
| Jun-30-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
3 Promising Penny Stocks With Market Caps Up To $600M - simplywall.st
ProKidney (PROK) to Release Quarterly Earnings on Monday - MarketBeat
ProKidney approaches pivotal research, funding crossroads for drug therapy - Winston-Salem Journal
ProKidney Names Greg Madison as Chief Commercial Officer - HarianBasis.co
ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel - Insider Monkey
[SCHEDULE 13D/A] PROKIDNEY CORP. Amended Major Shareholder Report - Stock Titan
Control Empresarial converts 63.1M PROK (NASDAQ: PROK) Paired Interests into Class A shares - Stock Titan
Culleton - Winston-Salem Journal
9 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
MSN Money - MSN
ProKidney spikes after mid-stage trial data for lead asset - MSN
ProKidney's top executive gains nearly threefold hike in 2025 compensation - Winston-Salem Journal
ProKidney (PROK) Stock Live Trade (On the Radar) 2026-04-20Late Breakout - Cổng thông tin điện tử tỉnh Lào Cai
ProKidney (NASDAQ:PROK) Upgraded to Sell at Wall Street Zen - MarketBeat
ProKidney (NASDAQ:PROK) Stock Price Up 9%Should You Buy? - MarketBeat
Executive pay, governance on agenda at ProKidney (NASDAQ: PROK) vote - Stock Titan
ProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ProKidney (PROK) Stock: Trend Strength (Buying Pressure) 2026-04-15AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
ProKidney (NASDAQ:PROK) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Bull Run: Can ProKidney Corp continue delivering strong returns2026 Key Highlights & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Winners Losers: Is ProKidney Corp impacted by rising rates2026 Market Sentiment & Fast Entry High Yield Stock Tips - baoquankhu1.vn
High stakes: ProKidney pushes toward commercialization as cash dwindles, opportunity awaits - The Business Journals
Is ProKidney (PROK) Stock suitable for dividend investors | Price at $1.88, Up 1.35%Fundamentals - Cổng thông tin điện tử tỉnh Lào Cai
Analysis Recap: Will ProKidney Corp benefit from government policyQuarterly Portfolio Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Can ProKidney (PROK) Stock Reach New Highs | Price at $1.81, Down 4.74%Social Buy Zones - Cổng thông tin điện tử tỉnh Lào Cai
April 2026 Penny Stock Highlights - Sahm
Hennion & Walsh Asset Management Inc. Has $3.37 Million Holdings in ProKidney Corp. $PROK - MarketBeat
PROK Stock Analysis: ProKidney Corp falls 2.23% to $1.75, testing key biotech support - Cổng thông tin điện tử tỉnh Tây Ninh
Analysis Recap: What is the long term forecast for ProKidney Corp stockTrade Performance Summary & Low Drawdown Trading Strategies - baoquankhu1.vn
What Makes ProKidney Corp. (PROK) So Attractive - Yahoo Finance
Sell Signal: Will ProKidney Corp benefit from geopolitical trendsTrade Risk Summary & Real-Time Market Trend Scan - baoquankhu1.vn
Revenue Check: Does ProKidney Corp outperform in volatile markets2026 Drop Watch & Consistent Profit Trading Strategies - baoquankhu1.vn
ProKidney (NASDAQ:PROK) Shares Up 5.9%Here's Why - MarketBeat
5 Best Penny Stocks That Could Triple Your Money - Insider Monkey
Investment Report: What are the future prospects of ProKidney Corp2026 Earnings Impact & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
ProKidney (MEX:PROK) PB Ratio : (As of Mar. 27, 2026) - GuruFocus
ProKidney hires chief commercial officer as key clinical test results near - Winston-Salem Journal
ProKidney names Greg Madison as chief commercial officer By Investing.com - Investing.com Australia
ProKidney appoints Greg Madison as chief commercial officer - TipRanks
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer - Bitget
ProKidney names Greg Madison as chief commercial officer - Investing.com
ProKidney expands senior leadership team with appointment of Greg Madison as chief commercial officer - marketscreener.com
ProKidney hires ex-Shield CEO Greg Madison for rilparencel launch prep - Stock Titan
Prokidney Expands Senior Leadership Team With Appointment Of Greg Madison As Chief Commercial Officer - TradingView
ProKidney (NASDAQ:PROK) Trading Down 7.6%Here's What Happened - MarketBeat
Q2 Earnings Forecast for ProKidney Issued By HC Wainwright - MarketBeat
ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Insider Sell: Does ProKidney Corp offer margin of safety2026 Outlook & Capital Efficiency Focused Ideas - baoquankhu1.vn
ProKidney A: Fundamental Analysis and Financial Ratings | PROK | KYG7S53R1049 - marketscreener.com
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability - The Globe and Mail
ProKidney (NASDAQ:PROK) Cut to Sell at Wall Street Zen - MarketBeat
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):